Sanara Medtech Inc (SMTI) said after close Monday that it lost $0.03 per share in quarter four 2023.
On the revenue line, the company reported $17.7 million, beating estimates by $1.2 million.
In the same quarter a year ago, the company lost $0.51 per share on revenue of $15.3 million.
The stock is up 2.07% to $37.00 after the report.
Despite revenues increasing, earnings decreased, signaling a decline in profit margins.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
Trading in the five days leading up to the report earned Sanara Medtech Inc a Bearish Sentiment Rank from InvestorsObserver.
Prior to the report, InvestorsObserver gave the stock an overall score of 38. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
News Home
Sanara Medtech Inc Up 2.07% To $37.00 After Earnings Beat
Mentioned in this article
